Observational Study to Assess Intravitreal Aflibercept Injections Used in a Treat and Extend Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)
An Observational Study to Assess the Use of Intravitreal Aflibercept Injections in a Routine Treat and Extend Regimen in Treatment-naïve Patients Diagnosed With Wet Age-related Macular Degeneration
Sponsor: Bayer
This observational or N/A phase trial investigates Wet Age-related Macular Degeneration and is currently completed. Bayer leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2023 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jul 2023 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
▶ Show 10 earlier versions
-
Feb 2019 — Sep 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Recruiting NA
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .